<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02856893</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-1613</org_study_id>
    <secondary_id>ESR-15-11406</secondary_id>
    <nct_id>NCT02856893</nct_id>
  </id_info>
  <brief_title>Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)</brief_title>
  <acronym>APPLE</acronym>
  <official_title>APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR Mutant NSCLC Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The phase II APPLE trial gives the opportunity to prospectively validate liquid biopsies as a&#xD;
      new standard for testing tumor progression compared with conventional radiological procedure&#xD;
      in EGFR mutant advanced NSCLC patients. Moreover based on the sequential T790M test during&#xD;
      treatment the investigators will assess the predictive value of liquid biopsies. APPLE trial&#xD;
      will examine the best strategy for delivering osimertinib (upfront versus sequential&#xD;
      treatment after 1st generation EGFR TKI) in EGFR mutant NSCLC patients. Finally, the trial&#xD;
      will also explore the mechanisms of acquired resistance to Osimertinib based on the results&#xD;
      of an optional biopsy upon progression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective To evaluate the best strategy for delivering Osimertinib (AZD9291) in NSCLC&#xD;
      patients with EGFR mutation. The objective is assessed by Progression Free Survival rate at&#xD;
      18 months (PFS-18).&#xD;
&#xD;
      Secondary objectives&#xD;
&#xD;
        -  To evaluate PFS on Osimertinib measured from randomization by RECIST criteria 1.1 [Ref&#xD;
           33].&#xD;
&#xD;
        -  To evaluate PFS measured from switching to Osimertinib by RECIST criteria 1.1 [Ref 33].&#xD;
&#xD;
        -  To determine the proportion of patients receiving Osimertinib based on the determination&#xD;
           of cfDNA T790M mutation positive.&#xD;
&#xD;
        -  To evaluate time to symptomatic brain metastases in patients with presence of brain&#xD;
           metastases at study entry.&#xD;
&#xD;
        -  To evaluate PFS-2 (defined as the sum of the PFS to Gefitinib and the PFS to Osimertinib&#xD;
           treatment).&#xD;
&#xD;
        -  To evaluate Overall Response Rate (ORR) to Osimertinib.&#xD;
&#xD;
        -  To evaluate the Treatment duration.&#xD;
&#xD;
        -  To evaluate Time to progression (TTP) on Osimertinib (measured from switching to&#xD;
           osimertinib).&#xD;
&#xD;
        -  To evaluate Overall Survival (OS).&#xD;
&#xD;
        -  To evaluate time to brain progression (TTBP).&#xD;
&#xD;
        -  Safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 10, 2017</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS Rate at 18 months</measure>
    <time_frame>24 months after first patient in</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS measured from switching to Osimertinib by RECIST criteria 1.1</measure>
    <time_frame>24 months after first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients receiving Osimertinib based on the determination of cfDNA T790M mutation positive</measure>
    <time_frame>24 months after first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression on Osimertinib</measure>
    <time_frame>through study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to symptomatic brain metastases in patients with presence of brain metastases at study entry</measure>
    <time_frame>24 months after first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) to Osimertinib</measure>
    <time_frame>24 months after first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment duration</measure>
    <time_frame>24 months after first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>24 months after first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to brain progression (TTBP)</measure>
    <time_frame>24 months after first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>24 months after first patient in</time_frame>
    <description>Number of participants with treatment-related adverse events by CTCAE version 4.0. Adverse events, serious adverse events and adverse reactions will be monitored.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Osimertinib till progression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Osimertinib until PD according to RECIST 1.1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gefitinib till + blood test/progression than Osimertinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gefitinib until emergence of positive T790M status (&quot;cfDNA T790M positive progression&quot;) followed by Osimertinib until second PD according to RECIST 1.1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gefitinib till progression than Osimertinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gefitinib until PD according to RECIST 1.1 followed by Osimertinib until PD according to RECIST 1.1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osimertinib</intervention_name>
    <description>Osimertinib 60 or 40 mg daily until progression</description>
    <arm_group_label>Gefitinib till + blood test/progression than Osimertinib</arm_group_label>
    <arm_group_label>Gefitinib till progression than Osimertinib</arm_group_label>
    <arm_group_label>Osimertinib till progression</arm_group_label>
    <other_name>AZD9291, Tagrisso</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
    <description>Gefitinib 250mg daily until progression</description>
    <arm_group_label>Gefitinib till + blood test/progression than Osimertinib</arm_group_label>
    <arm_group_label>Gefitinib till progression than Osimertinib</arm_group_label>
    <other_name>Iressa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
        Registration:&#xD;
&#xD;
          -  Pathological diagnosis of adenocarcinoma of the lung carrying common EGFR activating&#xD;
             mutations associated with EGFR-TKI sensitivity (Del19 or L858R); performed locally; no&#xD;
             other EGFR mutations will be allowed. In case of other (than EGFR) concomitant&#xD;
             mutations, discussion with EORTC Headquarters is mandatory;&#xD;
&#xD;
          -  Stage IV NSCLC;&#xD;
&#xD;
          -  Blood sample available for cfDNA EGFR T790M central testing;&#xD;
&#xD;
          -  Age ≥18 years;&#xD;
&#xD;
          -  EGFR TKI treatment-naïve eligible to receive first-line treatment with EGFR TKI;&#xD;
&#xD;
          -  Prior adjuvant and neo-adjuvant therapy is permitted (chemotherapy, radiotherapy,&#xD;
             investigational agents) if performed more than 12 months before registration;&#xD;
&#xD;
          -  Before patient registration/randomization, written informed consent must be given&#xD;
             according to ICH/GCP, and national/local regulations&#xD;
&#xD;
        Randomization:&#xD;
&#xD;
          -  Report of adequacy sample for cfDNA EGFR T790M test by central laboratory;&#xD;
&#xD;
          -  Prior palliative radiotherapy or surgery are allowed if completed at least 4 weeks&#xD;
             before the randomization;&#xD;
&#xD;
          -  Patients with brain metastases are allowed provided they are stable (i.e. without&#xD;
             evidence of progression by imaging for at least two weeks prior to the first dose of&#xD;
             trial treatment and without deterioration of any neurologic symptoms), and have not&#xD;
             received steroids for at least 7 days before randomization; Baseline tumor assessment&#xD;
             scans are done within 21 days before randomization;&#xD;
&#xD;
          -  Evaluable disease as defined below;&#xD;
&#xD;
          -  At least one lesion, not previously irradiated and not chosen for biopsy during the&#xD;
             study screening period, that can be accurately measured at baseline as ≥10 mm in the&#xD;
             longest diameter (except lymph nodes which must have a short axis of ≥15 mm) with&#xD;
             computed tomography (CT) or magnetic resonance imaging (MRI), and which is suitable&#xD;
             for accurate repeated measurements.&#xD;
&#xD;
          -  WHO Performance Status 0-2, with no clinically significant deterioration over the&#xD;
             previous 2 weeks and a minimum life expectancy of 12 weeks;&#xD;
&#xD;
          -  Adequate bone marrow, renal, hepatic and liver function within 21 days from&#xD;
             randomization and defined as follows:&#xD;
&#xD;
          -  Absolute neutrophil count ≥1.5 x 109/L;&#xD;
&#xD;
          -  Platelet count ≥100 x 109/L;&#xD;
&#xD;
          -  Haemoglobin ≥9 g/dL;&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) ≤2.5x the upper limit of normal (ULN) if no&#xD;
             demonstrable liver metastases or ≤5xULN in the presence of liver metastases;&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) ≤2.5xULN if no demonstrable liver metastases or&#xD;
             ≤5xULN in the presence of liver metastases;&#xD;
&#xD;
          -  Total bilirubin ≤1.5xULN if no liver metastases or ≤3xULN in the presence of&#xD;
             documented Gilbert's Syndrome (unconjugated hyperbilirubinaemia) or liver metastases;&#xD;
&#xD;
          -  Serum creatinine ≤1.5xULN concurrent with creatinine clearance ≥50 mL/min (measured or&#xD;
             calculated by Cockcroft and Gault equation);&#xD;
&#xD;
          -  No significant comorbidity that according to the investigator would hamper the&#xD;
             participation on the trial;&#xD;
&#xD;
          -  Female patients should be using adequate contraceptive measures, should not be&#xD;
             breastfeeding, until 12 months after the last dose, and must have a negative pregnancy&#xD;
             test (serum or urine) prior to first dose of study drug (within 72 hours); or female&#xD;
             patients must have an evidence of non-child-bearing potential by fulfilling one of the&#xD;
             following criteria at screening:&#xD;
&#xD;
          -  Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12&#xD;
             months following cessation of all exogenous hormonal treatments.&#xD;
&#xD;
          -  Women under 50 years old would be consider postmenopausal if they have been&#xD;
             amenorrheic for 12 months or more following cessation of exogenous hormonal treatments&#xD;
             and with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the&#xD;
             post-menopausal range for the institution.&#xD;
&#xD;
          -  Documentation of irreversible surgical sterilisation by hysterectomy,&#xD;
             bilateraloophorectomy, or bilateral salpingectomy but not tubal ligation.&#xD;
&#xD;
          -  Male patients should be willing to use barrier contraception, i.e., condoms&#xD;
&#xD;
             o Male patients will be advised to arrange for the freezing of sperm samples prior to&#xD;
             the start of the study should they wish to father children, and not to donate sperm&#xD;
             until 6 months after discontinuation of study treatment.&quot; (as per Investigator&#xD;
             Brochure, IB)&#xD;
&#xD;
          -  Absence of any psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule; those&#xD;
             conditions should be discussed with the patient before registration in the trial.&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          -  Treatment with any of the following:&#xD;
&#xD;
          -  Prior treatment with any systemic anti-cancer therapy for locally advanced/metastatic&#xD;
             NSCLC including chemotherapy, biologic therapy, immunotherapy, or any investigational&#xD;
             drug;&#xD;
&#xD;
          -  Prior treatment with an EGFR-TKI;&#xD;
&#xD;
          -  Major surgery (excluding placement of vascular access) within 4 weeks before&#xD;
             randomization;&#xD;
&#xD;
          -  Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of&#xD;
             radiation within 4 weeks before randomization&#xD;
&#xD;
          -  Patients currently receiving (or unable to stop use at least 1 week prior to receiving&#xD;
             the first dose of study drug) medications or herbal supplements known to be potent&#xD;
             inhibitors or inducers of cytochrome P450 (CYP) 3A4;&#xD;
&#xD;
          -  Other anti-cancer therapies and alternative medications such as homeopathic treatment,&#xD;
             etc;&#xD;
&#xD;
          -  Treatment with an investigational drug within five half-lives of the compound or any&#xD;
             of its related material, if known;&#xD;
&#xD;
          -  Leptomeningeal carcinomatosis; spinal cord compression;&#xD;
&#xD;
          -  Any unresolved toxicities from prior systemic therapy (e.g., adjuvant chemotherapy)&#xD;
             greater than CTCAE grade 2 at the time of randomization;&#xD;
&#xD;
          -  Patients will not be eligible if they have evidence of active malignancy (other than&#xD;
             non-melanoma skin cancer or localized cervical cancer or localised and presumed cured&#xD;
             prostatic cancer) within 2 years before randomization and are not receiving specific&#xD;
             treatment for these malignancies at baseline assessment;&#xD;
&#xD;
          -  Any evidence of severe or uncontrolled systemic diseases, including uncontrolled&#xD;
             hypertension and active bleeding diatheses, which in the Investigator's opinion makes&#xD;
             it undesirable for the patient to participate in the trial or which would jeopardise&#xD;
             compliance with the protocol; or active infection including hepatitis B, hepatitis C&#xD;
             and human immunodeficiency virus (HIV). Active infection will include any patients&#xD;
             receiving intravenous treatment for infection; active hepatitis B infection will, at a&#xD;
             minimum, include all patients who are Hepatitis B surface antigen positive (HbsAg&#xD;
             positive) based on serology assessment. Screening for chronic conditions is not&#xD;
             required;&#xD;
&#xD;
          -  Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to&#xD;
             swallow the formulated product, or previous significant bowel resection that would&#xD;
             preclude adequate absorption of Osimertinib or Gefitinib;&#xD;
&#xD;
          -  Any of the following cardiac criteria:&#xD;
&#xD;
          -  Mean resting corrected QT interval (QTc) &gt;470 msec, obtained from 3 ECGs using local&#xD;
             clinic ECG machine-derived QTcF value&#xD;
&#xD;
          -  Any clinically important abnormalities in rhythm, conduction, or morphology of resting&#xD;
             ECG, e.g., complete left bundle branch block, third-degree heart block, second-degree&#xD;
             heart block, PR interval &gt;250 msec or history of episodes of bradycardia (&lt;50 BPM);&#xD;
&#xD;
          -  Any factors that increase the risk of QTc prolongation or risk of arrhythmic events&#xD;
             such as heart failure, hypokalaemia, congenital long QT syndrome family history of&#xD;
             long QT syndrome, or unexplained sudden death under 40 years of age in first-degree&#xD;
             relatives or any concomitant medication known to prolong the QT interval.&#xD;
&#xD;
          -  Abnormal cardiac function: LVEF &lt; 50% (assessed by MUGA or ECHO)&#xD;
&#xD;
          -  Past medical history of ILD (Interstitial Lung Disease), drug-induced ILD, radiation&#xD;
             pneumonitis which required steroid treatment, or any evidence of clinically active&#xD;
             ILD.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafal Dziadziuszko, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mecical University of Gdansk, Poland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hopitalier Intercommunal De Creteil</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assistance Publique - Hopitaux de Marseille - Hopital Nord</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse - Hopital Larrey</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Hussein Cancer Center</name>
      <address>
        <city>Amman</city>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Gdansk</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinic Golnik</name>
      <address>
        <city>Golnik</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Institute Of Oncology</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Universitari de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital De La Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron Institut d'Oncologia</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital A Coruna-Hospital Teresa Herrera</name>
      <address>
        <city>Coruna</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 De Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia - ICO Badalona - Hospital De Mataro</name>
      <address>
        <city>Mataró</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virgen del Rocio University Hospital</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Jordan</country>
    <country>Poland</country>
    <country>Slovenia</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 11, 2016</study_first_submitted>
  <study_first_submitted_qc>August 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2016</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AZD9291</keyword>
  <keyword>Osimertinib</keyword>
  <keyword>Gefitinib</keyword>
  <keyword>NSCLC</keyword>
  <keyword>liquid biopsy</keyword>
  <keyword>ctDNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Osimertinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

